Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Ribociclib|DRUG: Letrozole|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Karolinska University Hospital